UA74767C2 - Method and composition for oral use of taxanes in patients - Google Patents

Method and composition for oral use of taxanes in patients Download PDF

Info

Publication number: UA74767C2
Authority: UA; Ukraine
Prior art keywords: paclitaxel; taxane; administration; agents; cyclosporin
Prior art date: 1997-05-27

Application number

UA99116450A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Baker Norton Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-27

Filing date

1998-04-22

Publication date

2006-02-15

1998-04-22 Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma

2006-02-15 Publication of UA74767C2 publication Critical patent/UA74767C2/uk

Links

229940123237 Taxane Drugs 0.000 title claims abstract description 55
238000000034 method Methods 0.000 title claims abstract description 45
239000000203 mixture Substances 0.000 title description 8
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 114
229930012538 Paclitaxel Natural products 0.000 claims abstract description 110
229960001592 paclitaxel Drugs 0.000 claims abstract description 110
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 45
108010036949 Cyclosporine Proteins 0.000 claims abstract description 43
229960001265 ciclosporin Drugs 0.000 claims abstract description 41
229930182912 cyclosporin Natural products 0.000 claims abstract description 35
229930105110 Cyclosporin A Natural products 0.000 claims abstract description 31
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims abstract description 22
206010020751 Hypersensitivity Diseases 0.000 claims abstract description 15
201000010099 disease Diseases 0.000 claims abstract description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
230000009610 hypersensitivity Effects 0.000 claims abstract description 7
239000003814 drug Substances 0.000 claims description 27
229940079593 drug Drugs 0.000 claims description 25
108010036941 Cyclosporins Proteins 0.000 claims description 16
206010028980 Neoplasm Diseases 0.000 claims description 16
239000002552 dosage form Substances 0.000 claims description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
229960003668 docetaxel Drugs 0.000 claims description 12
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 11
201000004792 malaria Diseases 0.000 claims description 4
206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
239000007788 liquid Substances 0.000 claims description 3
208000020816 lung neoplasm Diseases 0.000 claims description 3
208000030761 polycystic kidney disease Diseases 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
230000000451 tissue damage Effects 0.000 claims description 3
231100000827 tissue damage Toxicity 0.000 claims description 3
TYFOVYYNQGNDKH-HHPJSCBPSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23, Chemical compound CCCC[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC1=O TYFOVYYNQGNDKH-HHPJSCBPSA-N 0.000 claims description 2
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
KUSICUWKCBCAHV-ZSINMPTNSA-N [(e,1r,2r)-1-[(2s,5s,11s,14s,17s,20s,23r,26s,29s,32s)-5-ethyl-1,7,10,16,20,23,25,28,31-nonamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-14,32-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacont-2-y Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](OC(C)=O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O KUSICUWKCBCAHV-ZSINMPTNSA-N 0.000 claims description 2
230000015572 biosynthetic process Effects 0.000 claims description 2
108010040764 dihydrocyclosporin A Proteins 0.000 claims description 2
108010040786 dihydrocyclosporin C Proteins 0.000 claims description 2
208000014018 liver neoplasm Diseases 0.000 claims description 2
201000005202 lung cancer Diseases 0.000 claims description 2
208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Polymers CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 claims 1
238000005755 formation reaction Methods 0.000 claims 1
201000007270 liver cancer Diseases 0.000 claims 1
230000003211 malignant effect Effects 0.000 claims 1
239000008389 polyethoxylated castor oil Substances 0.000 claims 1
230000035755 proliferation Effects 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 abstract description 77
238000011282 treatment Methods 0.000 abstract description 21
230000002708 enhancing effect Effects 0.000 abstract description 15
238000009101 premedication Methods 0.000 abstract description 9
241000282414 Homo sapiens Species 0.000 abstract description 4
241000282412 Homo Species 0.000 description 21
238000001990 intravenous administration Methods 0.000 description 21
238000010521 absorption reaction Methods 0.000 description 20
230000000694 effects Effects 0.000 description 19
241000700159 Rattus Species 0.000 description 17
239000002246 antineoplastic agent Substances 0.000 description 16
238000001802 infusion Methods 0.000 description 16
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 15
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 15
230000001965 increasing effect Effects 0.000 description 14
230000036470 plasma concentration Effects 0.000 description 14
150000001875 compounds Chemical class 0.000 description 13
210000002381 plasma Anatomy 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
231100000419 toxicity Toxicity 0.000 description 10
230000001988 toxicity Effects 0.000 description 10
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
230000008685 targeting Effects 0.000 description 9
230000001506 immunosuppresive effect Effects 0.000 description 8
210000000936 intestine Anatomy 0.000 description 8
230000036457 multidrug resistance Effects 0.000 description 8
229940002612 prodrug Drugs 0.000 description 8
239000000651 prodrug Substances 0.000 description 8
230000036765 blood level Effects 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000011260 co-administration Methods 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
239000008177 pharmaceutical agent Substances 0.000 description 6
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 6
230000009885 systemic effect Effects 0.000 description 6
230000000259 anti-tumor effect Effects 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
229940126601 medicinal product Drugs 0.000 description 5
206010006187 Breast cancer Diseases 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
229940049937 Pgp inhibitor Drugs 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000037396 body weight Effects 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
229940127089 cytotoxic agent Drugs 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
239000002748 glycoprotein P inhibitor Substances 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
230000000968 intestinal effect Effects 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
108010078791 Carrier Proteins Proteins 0.000 description 3
206010012735 Diarrhoea Diseases 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
239000013543 active substance Substances 0.000 description 3
229940034982 antineoplastic agent Drugs 0.000 description 3
229940041181 antineoplastic drug Drugs 0.000 description 3
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
230000006870 function Effects 0.000 description 3
239000005414 inactive ingredient Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000002642 intravenous therapy Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
-1 other taxanes Chemical compound 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
229960001404 quinidine Drugs 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
239000002904 solvent Substances 0.000 description 3
230000032258 transport Effects 0.000 description 3
SYXYUKMELXLDBD-WKHWYDSQSA-N (3s,6r,9s,12s,15s,18s,24s,27s,30s,33s)-24-ethyl-27-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,6,9,13,19,22,28-octamethyl-3,12,18,33-tetrakis(2-methylpropyl)-15,30-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,2 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O SYXYUKMELXLDBD-WKHWYDSQSA-N 0.000 description 2
SYXYUKMELXLDBD-UHFFFAOYSA-N Cyclosporin E Natural products CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O SYXYUKMELXLDBD-UHFFFAOYSA-N 0.000 description 2
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
206010027457 Metastases to liver Diseases 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
101150053185 P450 gene Proteins 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
102000004243 Tubulin Human genes 0.000 description 2
108090000704 Tubulin Proteins 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
239000008298 dragée Substances 0.000 description 2
230000035622 drinking Effects 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
239000003596 drug target Substances 0.000 description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
229960005420 etoposide Drugs 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
206010073071 hepatocellular carcinoma Diseases 0.000 description 2
231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
239000000938 histamine H1 antagonist Substances 0.000 description 2
239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000007154 intracellular accumulation Effects 0.000 description 2
230000006122 isoprenylation Effects 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
210000000110 microvilli Anatomy 0.000 description 2
208000004235 neutropenia Diseases 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000035515 penetration Effects 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000001839 systemic circulation Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000004885 tandem mass spectrometry Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Polymers FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010055113 Breast cancer metastatic Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
206010018092 Generalised oedema Diseases 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000015728 Taxus canadensis Species 0.000 description 1
206010047141 Vasodilatation Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
206010000059 abdominal discomfort Diseases 0.000 description 1
231100000230 acceptable toxicity Toxicity 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
208000024783 anasarca Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000007321 biological mechanism Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
102220352928 c.35C>A Human genes 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229960003677 chloroquine Drugs 0.000 description 1
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
230000004087 circulation Effects 0.000 description 1
229940121657 clinical drug Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000013066 combination product Substances 0.000 description 1
229940127555 combination product Drugs 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229930004069 diterpene Natural products 0.000 description 1
150000004141 diterpene derivatives Chemical class 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000000576 food coloring agent Substances 0.000 description 1
235000002864 food coloring agent Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
201000003911 head and neck carcinoma Diseases 0.000 description 1
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940060367 inert ingredients Drugs 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
229960002418 ivermectin Drugs 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
238000013332 literature search Methods 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
230000002020 noncytotoxic effect Effects 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
150000002990 phenothiazines Chemical class 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000009290 primary effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
210000000512 proximal kidney tubule Anatomy 0.000 description 1
WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
229960000611 pyrimethamine Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
108091006024 signal transducing proteins Proteins 0.000 description 1
102000034285 signal transducing proteins Human genes 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000008137 solubility enhancer Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
230000032895 transmembrane transport Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1
239000002676 xenobiotic agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UA99116450A 1997-05-27 1998-04-22 Method and composition for oral use of taxanes in patients UA74767C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86351397A	1997-05-27	1997-05-27
PCT/US1998/007776 WO1998053811A1 (en)	1997-05-27	1998-04-22	Method and compositions for administering taxanes orally to human patients

Publications (1)

Publication Number	Publication Date
UA74767C2 true UA74767C2 (en)	2006-02-15

Family

ID=25341241

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA99116450A UA74767C2 (en)	1997-05-27	1998-04-22	Method and composition for oral use of taxanes in patients

Country Status (22)

Country	Link
EP (1)	EP0994706B1 (de)
JP (1)	JP2002500667A (de)
KR (1)	KR100615783B1 (de)
CN (2)	CN1261275A (de)
AR (1)	AR012731A1 (de)
AT (1)	ATE308365T1 (de)
AU (1)	AU7130098A (de)
BR (1)	BR9809694A (de)
CA (1)	CA2290446C (de)
CZ (1)	CZ9904244A3 (de)
DE (1)	DE69832173T2 (de)
DK (1)	DK0994706T3 (de)
ES (1)	ES2247690T3 (de)
HU (1)	HUP0003546A3 (de)
IL (2)	IL132992A0 (de)
NO (1)	NO995812L (de)
PL (1)	PL337064A1 (de)
RU (1)	RU2205005C2 (de)
SK (1)	SK157599A3 (de)
UA (1)	UA74767C2 (de)
WO (1)	WO1998053811A1 (de)
ZA (1)	ZA984268B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6964946B1 (en) *	1995-10-26	2005-11-15	Baker Norton Pharmaceuticals, Inc.	Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
SK182599A3 (en) *	1997-06-20	2000-07-11	Baker Norton Pharma	Soluble prodrugs of paclitaxel
GB9718903D0 (en)	1997-09-05	1997-11-12	Glaxo Group Ltd	Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU4955200A (en)	1999-05-17	2000-12-05	Cancer Research Ventures Limited	A method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs
RU2236226C2 (ru) *	1999-06-18	2004-09-20	Бейкер Нортон Фармасьютикалз, Инк.	Пероральные фармацевтические композиции, содержащие таксаны, и способы лечения с их применением
MXPA02004164A (es) *	1999-10-27	2002-10-17	Baker Norton Pharma	Metodo y composiciones para administrar taxanos por via oral a pacientes humanos.
KR20020013174A (ko) *	2000-08-11	2002-02-20	민경윤	경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
US7115565B2 (en)	2001-01-18	2006-10-03	Pharmacia & Upjohn Company	Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MXPA03006404A (es) *	2001-01-18	2004-12-02	Upjohn Co	Composiciones quimioterapeuticas de microemulsion de paclitaxel con biodisponibilidad oral mejorada.
SI1372636T1 (sl) *	2001-02-28	2006-12-31	Bristol Myers Squibb Co	Metronomsko odmerjanje taksanov za inhibiranje tumorske rasti
UY27185A1 (es) *	2001-02-28	2002-09-30	Bristol Myers Squibb Co	Dosificación metronómica de taxanos
US7063977B2 (en)	2001-08-21	2006-06-20	Bristol-Myers Squibb Company	Enzymatic resolution of t-butyl taxane derivatives
JP2008501708A (ja) *	2004-06-04	2008-01-24	スミスクラインビーチャム（コーク）リミテッド	がんの治療方法
GB0523659D0 (en) *	2005-11-21	2005-12-28	Novartis Ag	Organic compounds
AU2010256677A1 (en) *	2009-06-02	2012-01-12	Nikan Pharmaceuticals, Llc	Antagonism of human formyl peptide receptor for treatment of disease
EP4059497A1 (de) *	2021-03-17	2022-09-21	Dompé farmaceutici S.p.a.	C5ar1 inhibitoren zur behandlung von hypersensitivitätsreaktionen auf taxane
BR112023018826A2 (pt) *	2021-03-17	2024-03-12	Dompe Farm Spa	Inibidores de c5ar1 para tratamento de reações de hipersensibilidade a taxanos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5411947A (en) *	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
DE69120430D1 (de) *	1990-12-18	1996-07-25	Wellcome Found	Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
SG45403A1 (en) *	1991-01-11	1998-01-16	Glaxo Lab Sa	Acridine derivatives
US5567592A (en) *	1994-02-02	1996-10-22	Regents Of The University Of California	Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
HU222496B1 (hu) *	1994-07-26	2003-07-28	Indena S.P.A.	Félszintetikus taxánszármazékok, eljárás ezek előállítására, valamint ezeket tartalmazó gyógyászati készítmények
TW354293B (en) *	1995-06-06	1999-03-11	Bristol Myers Squibb Co	Prodrugs of paclitaxel derivatives
US5916566A (en) *	1995-06-07	1999-06-29	Avmax, Inc.	Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US6245805B1 (en) *	1995-10-26	2001-06-12	Baker Norton Pharmaceuticals, Inc.	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO1997027855A1 (en) *	1996-01-31	1997-08-07	Bristol-Myers Squibb Company	A method of making pharmaceutically active taxanes orally bioavailable
CA2258556A1 (en) *	1996-06-17	1997-12-24	Julian Stanley Kroin	Drug resistance and multidrug resistance modulators
GB9718903D0 (en) *	1997-09-05	1997-11-12	Glaxo Group Ltd	Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP1067908B9 (de) *	1998-04-01	2007-01-24	Jagotec Ag	Taxan-mikroemulsionen

1998
- 1998-04-22 WO PCT/US1998/007776 patent/WO1998053811A1/en not_active Ceased
- 1998-04-22 UA UA99116450A patent/UA74767C2/uk unknown
- 1998-04-22 AT AT98918361T patent/ATE308365T1/de not_active IP Right Cessation
- 1998-04-22 BR BR9809694-0A patent/BR9809694A/pt not_active IP Right Cessation
- 1998-04-22 EP EP98918361A patent/EP0994706B1/de not_active Expired - Lifetime
- 1998-04-22 SK SK1575-99A patent/SK157599A3/sk unknown
- 1998-04-22 JP JP50066399A patent/JP2002500667A/ja active Pending
- 1998-04-22 DE DE69832173T patent/DE69832173T2/de not_active Expired - Fee Related
- 1998-04-22 DK DK98918361T patent/DK0994706T3/da active
- 1998-04-22 HU HU0003546A patent/HUP0003546A3/hu unknown
- 1998-04-22 CZ CZ19994244A patent/CZ9904244A3/cs unknown
- 1998-04-22 IL IL13299298A patent/IL132992A0/xx active IP Right Grant
- 1998-04-22 AU AU71300/98A patent/AU7130098A/en not_active Abandoned
- 1998-04-22 RU RU99128033/14A patent/RU2205005C2/ru not_active IP Right Cessation
- 1998-04-22 KR KR1019997011000A patent/KR100615783B1/ko not_active Expired - Fee Related
- 1998-04-22 ES ES98918361T patent/ES2247690T3/es not_active Expired - Lifetime
- 1998-04-22 CA CA002290446A patent/CA2290446C/en not_active Expired - Fee Related
- 1998-04-22 CN CN98806440A patent/CN1261275A/zh active Pending
- 1998-04-22 CN CNA2004100304785A patent/CN1550231A/zh active Pending
- 1998-04-22 PL PL98337064A patent/PL337064A1/xx unknown
- 1998-05-20 ZA ZA984268A patent/ZA984268B/xx unknown
- 1998-05-21 AR ARP980102356A patent/AR012731A1/es unknown
1999
- 1999-11-17 IL IL132992A patent/IL132992A/en not_active IP Right Cessation
- 1999-11-26 NO NO995812A patent/NO995812L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HK1026637A1 (en)	2000-12-22
AR012731A1 (es)	2000-11-08
IL132992A0 (en)	2001-03-19
WO1998053811A1 (en)	1998-12-03
DE69832173T2 (de)	2006-08-03
JP2002500667A (ja)	2002-01-08
NO995812D0 (no)	1999-11-26
ATE308365T1 (de)	2005-11-15
HUP0003546A3 (en)	2002-12-28
CA2290446A1 (en)	1998-12-03
CA2290446C (en)	2008-01-29
RU2205005C2 (ru)	2003-05-27
KR20010013025A (ko)	2001-02-26
SK157599A3 (en)	2002-10-08
ZA984268B (en)	1999-06-23
DK0994706T3 (da)	2006-03-06
DE69832173D1 (de)	2005-12-08
EP0994706A1 (de)	2000-04-26
HUP0003546A2 (hu)	2002-11-28
EP0994706A4 (de)	2001-05-16
IL132992A (en)	2006-08-20
CN1261275A (zh)	2000-07-26
BR9809694A (pt)	2000-10-03
ES2247690T3 (es)	2006-03-01
CN1550231A (zh)	2004-12-01
AU7130098A (en)	1998-12-30
CZ9904244A3 (cs)	2001-10-17
PL337064A1 (en)	2000-07-31
KR100615783B1 (ko)	2006-08-25
NO995812L (no)	2000-01-25
EP0994706B1 (de)	2005-11-02

Publication	Publication Date	Title
AU698142B2 (en)	1998-10-22	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6730698B2 (en)	2004-05-04	Method and compositions for administering taxanes orally to human patients
RU2205005C2 (ru)	2003-05-27	Способ и композиции для перорального введения таксанов пациентам
KR20030019296A (ko)	2003-03-06	인체 환자에게 탁산을 경구 투여하는 방법 및 조성물
EP1634607A2 (de)	2006-03-15	Verfahren, Zusammensetzungen und Kits zur Erhöhung der oralen Bioverfügbarkeit von Pharmazeutika
AU784159B2 (en)	2006-02-16	Method and compositions for administering taxanes orally to human patients
HK1027967A (en)	2001-02-02	Method and compositions for administering taxanes orally to human patients
HK1026637B (en)	2006-01-06	Compositions for administering taxanes orally to human patients and their use
HK1001960B (en)	2006-01-27	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
MXPA99010850A (en)	2001-05-17	Method and compositions for administering taxanes orally to human patients